Adlane Soudani, CEO of Ipsen Pharma Algeria and Lyes Boudiaf, President and Founder of Isly Holding gave an interview to TSA, in which they return with more details on this project.
Your company Isly Holding has signed a partnership agreement with the Ipsen France laboratories, for the creation of a joint venture to produce essential drugs. Can you give us more details about this project?
Lyes Boudiaf: this project is based on a partnership agreement that was signed on Thursday, December 7, 2017 at the meeting of the Algerian-French High Level Intergovernmental Committee at the Hotel Matignon in Paris, in the presence of the two Algerian and French Prime Ministers , Ahmed Ouyahia and Edouard Philippe.
This investment consists in the creation of a mixed Algerian-French company governed by the law of foreign investment in Algeria, that is to say the 51/49 rule, between Ipsen, a world-renowned pharmaceutical company and the investment company Isly Holding which will give birth to Ipsen Pharma Algeria SAP.
This is a strong and exemplary signal of the collaboration between two French and Algerian private companies encouraged by the authorities of the two countries.
With this partnership between Isly and Ipsen, you intend to produce an anti-cancer drug, a first in Algeria. What is Decapeptyl and how important is it?
Adlane Soudani: This is a sustained-release peptide drug, Decapeptyl 3.75 mg and 11.25 mg, indicated for the treatment of advanced prostate cancer alone or in concomitant treatment with endometriosis. genital and extra-genital location, central precocious puberty, uterine fibroids and finally female infertility.
But you will also produce other drugs, more common use …
Adlane Soudani: We will proceed to a technology transfer to manufacture other drugs at subcontractors and local laboratories that already have the necessary equipment and know-how which the production process can be carried out by them.
This is Ipsen’s family health range: Smecta, Bedelix, Forlax and Tanakan. This is all the interest of the project, because we are going to build a factory of innovation whose production process does not exist in Algeria.
The installation of such an anti-cancer manufacturing plant is a first in Algeria. What is its interest and what will it bring to the Algerian pharmaceutical industry?
Lyes Boudiaf: Ipsen has only one factory in the world that manufactures Decapeptyl, the one that will be carried out in Algeria will be the second. It will also be a first in Africa.
The first added value is the availability of the product to meet the needs of the local market, this product representing an import envelope of 10 million euros that will be saved thanks to our investment.
We are also studying the possibility of exporting some products from our product range to neighboring markets and African countries.
How well will the manufacture of Decapeptyl actually be Algerian?
Adlane Soudani: we will be on a full process. There are, from memory, ten manufacturing steps that will be totally made in our factory in Algeria.
Can the plant cover the entire Algerian demand for Decapeptyl?
Adlane Soudani: That’s our goal. This plant will be able to meet the needs of Algerian patients. We will calibrate it so that it takes into account demand growth when it becomes operational 2021.
With this project, you are embarking on the manufacture of oncology drugs in Algeria, high-tech products. Will Ipsen’s know-how benefit the Algerian pharmaceutical industry and industry workers?
Adlane Soudani: innovating to better care is the motto of Ipsen, we are in a logic of sustainable investment and we are quite optimistic about the economic evolution of our investment in Algeria.
Lyes Boudiaf: the transfer of technology, innovation, the creation of highly qualified jobs, the contribution to the satisfaction of national needs for drugs of this type constitute our guidelines. We are aware of entering a vital area to meet the needs of public health and meet the demand of patients and practitioners.
I trust the skills of my compatriots to participate in this beautiful project because we will call on them for this project to bear fruit.
Many investors and economists believe that the 51/49 rule is a brake on foreign investment in Algeria. The realization of your project has not been complicated by this rule?
Lyes Boudiaf: the two partners recognized that the investment structure 51/49 was not a hindrance because it is not only the financial investment, there is an investment of innovation and technology and above all, management.
In the mixed company, we have divided the tasks so that each of the two parties makes and controls his profession.